The Prediction of Type 1 Diabetes by Multiple Autoantibody Levels and Their Incorporation Into an Autoantibody Risk Score in Relatives of Type 1 Diabetic Patients
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We assessed whether a risk score that incorporates levels of multiple islet autoantibodies could enhance the prediction of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS: TrialNet Natural History Study participants (n = 784) were tested for three autoantibodies (GADA, IA-2A, and mIAA) at their initial screening. Samples from those positive for at least one autoantibody were subsequently tested for ICA and ZnT8A. An autoantibody risk score (ABRS) was developed from a proportional hazards model that combined autoantibody levels from each autoantibody along with their designations of positivity and negativity. RESULTS: The ABRS was strongly predictive of T1D (hazard ratio [with 95% CI] 2.72 [2.23-3.31], P < 0.001). Receiver operating characteristic curve areas (with 95% CI) for the ABRS revealed good predictability (0.84 [0.78-0.90] at 2 years, 0.81 [0.74-0.89] at 3 years, P < 0.001 for both). The composite of levels from the five autoantibodies was predictive of T1D before and after an adjustment for the positivity or negativity of autoantibodies (P < 0.001). The findings were almost identical when ICA was excluded from the risk score model. The combination of the ABRS and the previously validated Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) predicted T1D more accurately (0.93 [0.88-0.98] at 2 years, 0.91 [0.83-0.99] at 3 years) than either the DPTRS or the ABRS alone (P ≤ 0.01 for all comparisons). CONCLUSIONS: These findings show the importance of considering autoantibody levels in assessing the risk of T1D. Moreover, levels of multiple autoantibodies can be incorporated into an ABRS that accurately predicts T1D.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (55,74,75).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, the risk of type 1 diabetes increases as the number of relevant autoantibodies detected increases (53,74,75).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [75]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A leisurely look at the bootstrap, the jackknife, and cross-validation
Efron, B., & Gong, G. (1983) · The American Statistician · doi:10.1080/00031305.1983.10483087 · Cited by 3,229 · cited 1×
“A leave-one-out procedure was used for cross-validation (19).”
MethodTime‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker
Heagerty, P. J., Lumley, T., & Pepe, M. S. (2000) · Biometrics · doi:10.1111/j.0006-341x.2000.00337.x · Cited by 2,854 · cited 1×
“Areas under receiver operating characteristic (ROC) curves, adjusted for length of follow-up (20), were used to assess the accuracy of the scores.”
MethodChristakis, D., Richards, J. A., Zimmerman, F. J., Garrison, M. M., Xu, D., & Yapanel, U. H. (2009) · Cited by 2,289
The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes
Wenzlau, J. M., Juhl, K., Yu, L., Moua, O., Sarkar, S. A., Gottlieb, P., Rewers, M., Eisenbarth, G. S., Jensen, J., Davidson, H. W., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705894104 · Cited by 1,014
Self-citationEffects of insulin in relatives of patients with type 1 diabetes mellitus
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012350 · Cited by 836
Verge, C. F., Gianani, R., Kawasaki, E., Yu, L., Pietropaolo, M., Chase, H. P., Eisenbarth, G. S., & Jackson, R. A. (1996) · Diabetes · doi:10.2337/diab.45.7.926 · Cited by 827
Self-citationEffects of Oral Insulin in Relatives of Patients With Type 1 Diabetes
The Diabetes Prevention Trial-Type 1 Study Group (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1068 · Cited by 668
Ziegler, A. G., Hummel, M., Schenker, M., & Bonifacio, E. (1999) · Diabetes · doi:10.2337/diabetes.48.3.460 · Cited by 645
The Pathogenesis and Natural History of Type 1 Diabetes
Atkinson, M. A. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a007641 · Cited by 314 · cited 1×
“Although confirmatory data are not available, this possibility is suggested by the earlier appearance of autoantibody abnormalities than of overt metabolic abnormalities in the natural history of T1D (30).”
BackgroundKulmala, P., Savola, K., Petersen, J. S., Vähäsalo, P., Karjalainen, J., Löppönen, T., Dyrberg, T., Akerblom, H. K., & Knip, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci119879 · Cited by 287
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Gaglia, J. L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s002 · Cited by 2,086
(2) Classification and diagnosis of diabetes
American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc15-s005 · Cited by 1,841
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
Katsarou, A., Gudbjörnsdottir, S., Rawshani, A., Dabelea, D., Bonifacio, E., Anderson, B. J., Jacobsen, L. M., Schatz, D. A., & Lernmark, Å. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.16 · Cited by 1,475
Self-citation2. Diagnosis and classification of diabetes: standards of care in diabetes-2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Ebekozien, O., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s002 · Cited by 1,393
Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care · doi:10.2337/dc15-1419 · Cited by 1,216
Self-citation2. Classification and Diagnosis of Diabetes
American Diabetes Association (2016) · Diabetes Care · doi:10.2337/dc16-s005 · Cited by 1,066
Pathogenesis of autoimmune disease
Pisetsky, D. S. (2023) · Nature Reviews Nephrology · doi:10.1038/s41581-023-00720-1 · Cited by 649
2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s002 · Cited by 473
Influence of Vitamin D on Islet Autoimmunity and Beta-Cell Function in Type 1 Diabetes
Infante, M., Ricordi, C., Sanchez, J., Clare-Salzler, M. J., Padilla, N., Fuenmayor, V., Chavez, C., Alvarez, A., Baidal, D., Alejandro, R., et al. (2019) · Nutrients · doi:10.3390/nu11092185 · Cited by 272
Predicting Type 1 Diabetes Using Biomarkers
Bonifacio, E. (2015) · Diabetes Care · doi:10.2337/dc15-0101 · Cited by 191
He, L., Song, Y.-X., Zhu, T., Gu, W., & Liu, C. (2022) · Journal of Diabetes Research · doi:10.1155/2022/5953562 · Cited by 145
Jacobsen, L. M., Bocchino, L., Evans-Molina, C., DiMeglio, L., Goland, R., Wilson, D. M., Atkinson, M. A., Aye, T., Russell, W. E., Wentworth, J. M., et al. (2020) · Diabetologia · doi:10.1007/s00125-019-05047-w · Cited by 133
“Autoantibody titre also appears to affect the risk of type 1 diabetes [7, 18, 33, 34] and would be valuable data to add in future studies.”
BackgroundSelf-citationNoninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients
Gaglia, J. L., Harisinghani, M., Aganj, I., Wojtkiewicz, G. R., Hedgire, S., Benoist, C., Mathis, D., & Weissleder, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424993112 · Cited by 123
Autoantibodies 2015: From diagnostic biomarkers toward prediction, prognosis and prevention
Damoiseaux, J. G. M. C., Andrade, L. E. C., Fritzler, M. J., & Shoenfeld, Y. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.01.017 · Cited by 111
Other complications and diabetes-associated conditions in children and adolescents
Kordonouri, O., Klingensmith, G., Knip, M., Holl, R. W., Aanstoot, H.-J., Menon, P. S., & Craig, M. E. (2014) · Pediatric Diabetes · doi:10.1111/pedi.12183 · Cited by 94
Burbelo, P. D., Lebovitz, E. E., & Notkins, A. L. (2014) · Translational research · doi:10.1016/j.trsl.2014.08.006 · Cited by 93
HbA1c Predicts Time to Diagnosis of Type 1 Diabetes in Children at Risk
Helminen, O., Aspholm, S., Pokka, T., Hautakangas, M.-R., Haatanen, N., Lempainen, J., Ilonen, J., Simell, O., Knip, M., & Veijola, R. (2015) · Diabetes · doi:10.2337/db14-0497 · Cited by 85
Curcumin ameliorates autoimmune diabetes. Evidence in accelerated murine models of type 1 diabetes
Castro, C. N., Tabarrozzi, A. E. B., Winnewisser, J., Gimeno, M. L., Antunica-Noguerol, M., Liberman, A. C., Paz, D. A., Dewey, R. A., & Perone, M. J. (2014) · Clinical & Experimental Immunology · doi:10.1111/cei.12322 · Cited by 91
“It is possible to predict with a certain degree of accuracy those candidates that will progress to T1DM much before the appearance of clinical manifestations and prediction can be determined by measuring serum levels of autoantibodies in relatives of T1DM patients [5].”
BackgroundTissue-Specific Methylation of Human Insulin Gene and PCR Assay for Monitoring Beta Cell Death
Husseiny, M. I., Kaye, A., Zebadua, E., KANDEEL, F. R., & Ferreri, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094591 · Cited by 87
“Several effective predictive biomarkers for progression to T1D have been described such as HLA [24] and other genotypes [25], autoantibodies [26], and autoreactive T-cell assays [27–30].”
BackgroundPreclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review
Deane, K. D. (2014) · Current Rheumatology Reports · doi:10.1007/s11926-014-0419-6 · Cited by 77
Dynamics of Islet Autoantibodies During Prospective Follow-Up From Birth to Age 15 Years
Pöllänen, P. M., Ryhänen, S. J., Toppari, J., Ilonen, J., Vähäsalo, P., Veijola, R., Siljander, H., & Knip, M. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa624 · Cited by 72
Diabetes mellitus type 2 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Sukhareva, O. Y., Galstyan, G. R., Tokmakova, A. Y., Nikonova, T. V., Surkova, E. V., Кононенко, И. В., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12507 · Cited by 69
Wilson, D. M., Pietropaolo, S. L., Acevedo-Calado, M., Huang, S., Anyaiwe, D., Scheinker, D., Steck, A. K., Vasudevan, M. M., McKay, S. V., Sherr, J. L., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1297 · Cited by 56
Self-citationSosenko, J. M., Skyler, J. S., Mahon, J., Krischer, J. P., Greenbaum, C. J., Rafkin, L. E., Beam, C. A., Boulware, D. C., Matheson, D., Cuthbertson, D., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2359 · Cited by 60
Self-citationSchweiger, D. Š., Mendez, A., Jamnik, S. K., Bratanič, N., Bratina, N., Battelino, T., Brecelj, J., & Vidan‐Jeras, B. (2016) · Autoimmunity · doi:10.3109/08916934.2016.1164144 · Cited by 59
“Autoantibodies directed toward insulin (IAA) and beta cell-specific antigens, glutamic acid decarboxylase 65 (GAD65), insulinoma-associated antigen 2 (IA-2) and zinc transporter 8 (ZnT8) are considered diagnostic at disease onset, as well as during the preclinical phase of the disease [4].”
BackgroundDisease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice
Greenbaum, C., VanBuecken, D., & Lord, S. (2019) · Drugs · doi:10.1007/s40265-018-1035-y · Cited by 52
Genetic Risk Scores for Type 1 Diabetes Prediction and Diagnosis
REDONDO, M. J., Oram, R. A., & Steck, A. K. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0961-5 · Cited by 61
Zhao, Z., Miao, D., Michels, A. W., Steck, A. K., Dong, F., Rewers, M., & Yu, L. (2016) · Journal of Immunological Methods · doi:10.1016/j.jim.2016.01.011 · Cited by 52
“The presence of iAbs, their number (Bingley, 2010; Yu et al., 2012a; Steck et al., 2011) and levels (Sosenko et al., 2011, 2013; Vehik et al., 2011), are currently used to stage diabetes risk and as inclusion criteria into prevention trials (Schlosser et al., 2010).”
Self-citationNarendran, P., Jackson, N., Daley, A., Thompson, D., Stokes, K., Greenfield, S., Charlton, M., Curran, M., Solomon, T. P. J., Nouwen, A., et al. (2017) · Diabetic Medicine · doi:10.1111/dme.13439 · Cited by 54
Honardoost, M. A., Adinatha, A., Schmidt, F., Ranjan, B., Ghaeidamini, M., Rayan, N. A., Lim, M. G. L., Joanito, I., Lin, Q. X. X., Rajagopalan, D., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01300-z · Cited by 52
“…disease-predisposing human leukocyte antigen (HLA) haplotypes [17, 18], by revealing insulin, GAD-65, and IA-2A as well as β cells proteins as common autoantigens [19–21], and by identifying common aberrations in cell composition and gene expression in peripheral immune cells [6, 7, 22–25].”
BackgroundScreening for T1D risk to reduce DKA is not economically viable
Meehan, C., Fout, B. T., Ashcraft, J., Schatz, D., & Haller, M. J. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12313 · Cited by 48
Self-citationEndesfelder, D., zu Castell, W., Bonifacio, E. E., Rewers, M., Hagopian, W., She, J., Lernmark, Å., Toppari, J., Vehik, K., Williams, A. J. K., et al. (2018) · Diabetes · doi:10.2337/db18-0594 · Cited by 49
Self-citationImmuno-ecology: how the microbiome regulates tolerance and autoimmunity
Paun, A., & Danska, J. S. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.09.004 · Cited by 50
Endesfelder, D., Hagen, M., Winkler, C., Haupt, F., Zillmer, S., Knopff, A., Bonifacio, E. E., Ziegler, A., zu Castell, W., & Achenbach, P. (2016) · Diabetologia · doi:10.1007/s00125-016-4050-0 · Cited by 45
“With respect to islet autoantibodies, some of these features are known [12–21].”
BackgroundAltered Tim-1 and IL-10 Expression in Regulatory B Cell Subsets in Type 1 Diabetes
Liu, Y., Chen, Z., Qiu, J., Chen, H., & Zhou, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773896 · Cited by 43
“Diabetes-related autoantibodies can be used to assess the progression of T1D (31), and the titres of autoantibodies also seem to affect the complications of T1D (32, 33).”
BackgroundPredictors of slow progression to diabetes in children with multiple islet autoantibodies
Steck, A. K., Dong, F., Waugh, K., Frohnert, B. I., Yu, L., Norris, J. M., & Rewers, M. J. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.05.010 · Cited by 40
“In TrialNet, an autoantibody risk score (ABRS) (25) was developed from a proportional J Autoimmun.”
MethodSelf-citationDysglycemia and Index60 as Prediagnostic End Points for Type 1 Diabetes Prevention Trials
Nathan, B. M., Boulware, D. C., Geyer, S. M., Atkinson, M. A., Colman, P. G., Goland, R., Russell, W. E., Wentworth, J. M., Wilson, D. M., Evans‐Molina, C., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0916 · Cited by 38
Self-citationSteck, A. K., Fouts, A., Miao, D., Zhao, Z., Dong, F., Sosenko, J. M., Gottlieb, P. A., Rewers, M., Yu, L., & and the TrialNet Study Group (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0316 · Cited by 41
“Different risk scores for type 1 diabetes have been proposed, including number and levels of Ab as well as metabolic markers.(9,10,20,21) Currently, prevention trials are only available for relatives of patients with diabetes who have two or more Abs.”
Self-citationThe changing face of paediatric diabetes
SHAH, A. S., & Nadeau, K. J. (2020) · Diabetologia · doi:10.1007/s00125-019-05075-6 · Cited by 41
“Risk scores to predict the diagnosis of type 1 diabetes based on type and concentration of antibody are available [32].”
BackgroundThe Development, Validation, and Utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS)
Groups, T. D. T. 1. T. A. D. P. T.-T. 1. S., Sosenko, J. M., Skyler, J. S., & Palmer, J. P. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0626-1 · Cited by 31
Self-citationREDONDO, M. J., Sosenko, J. M., Libman, I. M., MCVEAN, J. J. F., Tosur, M., Atkinson, M. A., BECKER, D. J., & Geyer, S. M. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz296 · Cited by 31
Self-citationFouts, A., Pyle, L. L., Yu, L., Miao, D., Michels, A. W., Krischer, J. P., Sosenko, J. M., Gottlieb, P. A., Steck, A. K., & the Type 1 Diabetes TrialNet Study Group (2016) · Diabetes Care · doi:10.2337/dc16-0302 · Cited by 31
Self-citationBeta cell function in type 1 diabetes determined from clinical and fasting biochemical variables
the Type 1 Diabetes TrialNet Study Group, Wentworth, J. M., the Immune Tolerance Network Study Group, Bediaga, N. G., Giles, L. C., Ehlers, M. R., Gitelman, S. E., Geyer, S. M., Evans‐Molina, C., & Harrison, L. C. (2018) · Diabetologia · doi:10.1007/s00125-018-4722-z · Cited by 31
Possible heterogeneity of initial pancreatic islet beta‐cell autoimmunity heralding type 1 diabetes
Lernmark, Å., Akolkar, B., Hagopian, W., Krischer, J. P., McIndoe, R., Rewers, M., Toppari, J., Vehik, K., Ziegler, A., & The TEDDY Study Group (2023) · Journal of Internal Medicine · doi:10.1111/joim.13648 · Cited by 32
Self-citationThe role of B cells in the pathogenesis of type 1 diabetes
Wang, Y., Li, R., Huang, Y., Chen, H., Nie, H., Liu, L., Zou, X., Zhong, J., Zheng, B., & Gong, Q. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450366 · Cited by 28
Transcriptomic Segregation of Human Autoantigens Useful for the Diagnosis of Autoimmune Diseases
Burbelo, P. D., Iadarola, M. J., Alevizos, I., & Sapio, M. R. (2016) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0211-6 · Cited by 28
Sosenko, J. M., Yu, L., Skyler, J. S., Krischer, J. P., Gottlieb, P. A., Boulware, D. C., Miao, D., Palmer, J. P., & Steck, A. K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0243 · Cited by 28
Self-citationPersson, M., Becker, C., Larsson, H. E., Lernmark, Å., Forsander, G., Ivarsson, S. A., Ludvigsson, J., Samuelsson, U., Marcus, C., & Carlsson, A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.057 · Cited by 27
Japp, A. S., Meng, W., Rosenfeld, A. M., Perry, D. J., Thirawatananond, P., Bacher, R. L., Liu, C., Gardner, J. S., Atkinson, M. A., Kaestner, K. H., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.035 · Cited by 29
Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes
Greenbaum, C. J., Lord, S. M., & VanBuecken, D. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0932-x · Cited by 25
Packard, T. A., Smith, M. J., Conrad, F., Johnson, S. A., Getahun, A., Lindsay, R. S., Hinman, R. M., Friedman, R. S., Thomas, J. W., & Cambier, J. C. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm5110098 · Cited by 22
“activation, serum anti-insulin antibodies are found in T1D patients; often appearing before clinical onset, and when found in conjunction with other islet-reactive antibodies, they are a good biomarker of disease risk [2].”
BackgroundType 1 Diabetes Mellitus and Vitamin D
Durá-Travé, T., & Gallinas-Victoriano, F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104593 · Cited by 24
Strollo, R., Vinci, C., Napoli, N., Fioriti, E., Maddaloni, E., Åkerman, L., Casas, R., Pozzilli, P., Ludvigsson, J., & Nissim, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3132 · Cited by 22
Staging the progression to type 1 diabetes with prediagnostic markers
Sosenko, J. M. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000267 · Cited by 25
Self-citationDiabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 26
“• Рекомендуется определение содержания антител к антигенам островковых клеток поджелудочной железы в крови (GADA, ICA, IAA, IA-2A, Zn-T8A) лицам с подозрением на СД 1 для дифференциальной диагностики с другими типами СД [23, 24].”
Grace, S. L., Bowden, J., Walkey, H. C., Kaur, A., Misra, S., Shields, B. M., McKinley, T. J., Oliver, N. S., McDonald, T. J., Johnston, D. G., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac507 · Cited by 19
Gut microbiome and metabolic activity in type 1 diabetes: An analysis based on the presence of GADA
Luo, S., Yue, T., Liu, Z., Yang, D., Xu, M., Ding, Y., Jiang, W., Xu, W., Yan, J., Weng, J., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.938358 · Cited by 20
“Exclusion criteria were: (1) use of antibiotics in the three months before study enrollment; (2) significant acute or other chronic illnesses including diseases of the digestive tract, severe psychiatric diseases; (3) abdominal surgery history; (4) dietary supplements including prebiotic, probiotic, or fiber-rich supp…”
BackgroundKhan, W. A. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.68834 · Cited by 24
Ng, K., Stavropoulos, H., Anand, V., Veijola, R., Toppari, J., Maziarz, M., Lundgren, M., Waugh, K., Frohnert, B. I., Martin, F., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0878 · Cited by 23
Michels, A. W., & Ostrov, D. A. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.06.024 · Cited by 20
“In autoimmune diabetes, for example, patients can generate T cell responses and autoantibodies directed against insulin, glutamic acid decarboxylase (GAD), islet antigen 2, and a zinc transporter (17, 18).”
BackgroundSkärstrand, H., Krupinska, E., Haataja, T., Vaziri‐Sani, F., Lagerstedt, J. O., & Lernmark, Å. (2015) · Clinical & Experimental Immunology · doi:10.1111/cei.12448 · Cited by 17
Sperling, M. A., Tamborlane, W. V., Battelino, T., WEINZIMER, S. A., & Phillip, M. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-4858-7.00028-7 · Cited by 17
Nicholas, C. A., Tensun, F., Evans, S. A., Toole, K. P., Prendergast, J. E., BRONCUCIA, H. C., Hesselberth, J. R., Gottlieb, P. A., Wells, K. L., & Smith, M. J. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115425 · Cited by 15
“16,17 Accumulation of multiple autoantibodies in individuals with pre-clinical diabetes (prediabetes) is strongly correlated with faster progression to T1D diagnosis.”
Ng, K., Anand, V., Stavropoulos, H., Veijola, R., Toppari, J., Maziarz, M., Lundgren, M., Waugh, K., Frohnert, B. I., Martin, F., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05799-y · Cited by 16
“In general, using IAb levels improved prediction over just using IAb positivity indicators, consistent with observations from previous studies [16, 31].”
ResultBeyond Stages: Predicting Individual Time Dependent Risk for Type 1 Diabetes
Pribitzer, S., O’Rourke, C., Ylescupidez, A., Smithmyer, M. E., Bender, C., Speake, C., Lord, S. M., & Greenbaum, C. J. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae292 · Cited by 13
Felton, J. L., Conway, H., & Bonami, R. H. (2021) · Biomedicines · doi:10.3390/biomedicines9010042 · Cited by 13
Latent and Overt Polyautoimmunity in Children and Adolescents With Immune Thrombocytopenia
Kamioka, P. E., Liphaus, B. L., Beatrice, J. M., Matsumoto, L. C., Reis, J. M. A., Lima, L., Carneiro-Sampaio, M. M. S., & Carneiro, J. D. A. (2020) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000001836 · Cited by 13
Type 1 diabetes prediction in autoantibody-positive individuals: performance, time and money matter
Ferrat, L. A., Templeman, E. L., Steck, A. K., Parikh, H. M., You, L., Önengüt-Gümüşcü, S., Gottlieb, P. A., Triolo, T. M., Rich, S. S., Krischer, J. P., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06434-2 · Cited by 11
“Use of combinations of these variables has resulted in promising models [7–9] and scores such as the Diabetes Prevention Trial – type 1 risk score (DPTRS) [10], DPTRS 60 [11], Model 120 (M 120 ) [12], Index 60 [13], the Cox proportional hazard model (CPH) [14] and the likelihood ratio model (LR)…”
Self-citationSperling, M. A., Wolfsdorf, J. I., Menon, R. K., Tamborlane, W. V., Maahs, D. M., Battelino, T., & Phillip, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00021-x · Cited by 13
Kwon, B. C., Achenbach, P., Anand, V., Frohnert, B. I., Hagopian, W., Hu, J., Koski, E., Lernmark, Å., Lou, O., Martin, F., et al. (2022) · Diabetes · doi:10.2337/db22-0360 · Cited by 11
Joosse, B. A., Jackson, J. H., Cisneros, A., Santhin, A. B., Smith, S. A., Moore, D. J., Crofford, L. J., Wilfong, E. M., & Bonami, R. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.685718 · Cited by 11
“org 7 Insulin is a major autoantigen in type 1 diabetes and insulin autoantibodies are one of five islet autoantibodies used by Type 1 Diabetes TrialNet to identify individuals at high risk for type 1 diabetes (3).”
Backgroundthe DiAPREV-IT study group, Larsson, H. E., Larsson, C., & Lernmark, Å. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0680-1 · Cited by 11
Neuropeptide Y is a minor autoantigen in newly diagnosed type 1 diabetes patients
Skärstrand, H., Vaziri‐Sani, F., Delli, A. J., Törn, C., Larsson, H. E., Ivarsson, S. A., Agardh, D., Lernmark, Å., & the Skåne study group (2014) · Pediatric Diabetes · doi:10.1111/pedi.12222 · Cited by 10
“This notion is supported because multiple studies have shown that the larger the number of autoantibodies the greater the risk for progression to clinical diagnosis of T1D (20, 21).”
Nucleic acid biomarkers of β cell stress and death in type 1 diabetes
Syed, F., & Evans‐Molina, C. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000261 · Cited by 11
Svensson, M., Ramelius, A., Nilsson, A. ‐., Delli, A. J., Larsson, H. E., Carlsson, A., Forsander, G., Ivarsson, S. A., Ludvigsson, J., Kockum, I. S., et al. (2014) · Scandinavian Journal of Immunology · doi:10.1111/sji.12138 · Cited by 10
The Type 1 Diabetes Signature: Hardwired to Trigger Inflammation?
Coppieters, K. T., & von Herrath, M. G. (2014) · Diabetes · doi:10.2337/db14-0824 · Cited by 8
Grönholm, J., & Lenardo, M. J. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.11.007 · Cited by 8
Kelly, C. S., Wolf, W. A., CORNELIUS, E. M., Peter, M. E., CHAPMAN, K. S. M., & Dunne, J. L. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01637-z · Cited by 7
“Current clinical guidance suggests measuring autoantibodies in symptomatic individuals when a T1D diagnosis is suspected or when a type 2 diabetes mellitus progression occurs faster than expected [6–8].”
BackgroundMinasian, V., & Nazari, M. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122114 · Cited by 7
Kinney, M., You, L., Sims, E. K., Wherrett, D. K., Schatz, D., Lord, S. M., Krischer, J. P., Russell, W. E., Gottlieb, P. A., Libman, I. M., et al. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad003 · Cited by 6
Self-citationMartinez, M. M., Spiliopoulos, L., Salami, F., Agardh, D., Toppari, J., Lernmark, Å., Kero, J. T., Veijola, R., Tossavainen, P. H., Palmu, S. A., et al. (2021) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-021-00135-6 · Cited by 7
“Although ZnT8A are only considered as a useful additional risk marker [30], perhaps considering their levels [31], our previous [15] and present observation would require further studies into the association between ZnT8(W/R/Q)A and deteriorating beta-cell function.”
ResultOn the road to universal screening for risk of type 1 diabetes
REDONDO, M. J. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00166-8 · Cited by 6
Lin, N., Bai, L., Liu, Q., Chen, J., Ren, H., Guan, H., & Lü, Q. (2023) · BMC Neurology · doi:10.1186/s12883-023-03182-x · Cited by 5
“Anti-GAD Abs are found in T1DM patients and in first-degree relatives and are a marker for predicting the risk of diabetes [22].”
BackgroundBaseline Insulin Secretion Determines Response to Abatacept in Stage 1 Type 1 Diabetes
Galderisi, A., Carr, A. L. J., Taylor, P. N., Bonet, J., Cuthbertson, D. D., Sosenko, J. M., Sims, E. K., Evans‐Molina, C., Man, C. D., Ismail, H. M., et al. (2025) · Diabetes · doi:10.2337/db25-0801 · Cited by 4
Self-citationEconomic analysis of diabetes type 1 screening in children in the Russian Federation
Nedogoda, S. V., Galstyan, G. R., Лаптев, Д. Н., Salasyuk, A. S., Barykina, I. N., Lutova, V. O., & Popova, E. A. (2024) · Medical Technologies Assessment and Choice · doi:10.17116/medtech202446031104 · Cited by 4
Biobanking for Translational Diabetes Research in India
Gangadharan, C., Wills, S., Vangala, R. K., & Sigamani, A. (2020) · BioResearch open access · doi:10.1089/biores.2019.0052 · Cited by 4
Summary of the Type 1 Diabetes Genetics Consortium Autoantibody Workshop
Rich, S. S., & CONCANNON, P. J. (2015) · Diabetes Care · doi:10.2337/dcs15-2008 · Cited by 4
Lernmark, Å. (2013) · Diabetologia · doi:10.1007/s00125-013-3041-7 · Cited by 4
Yang, P., Bao, H., Sun, G., & Zhang, Y. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110646 · Cited by 3
What defines disease in an age of genetics and biomarkers?
Gottlieb, P. A. (2015) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000172 · Cited by 2
Beta cell function in the early stages of type 1 diabetes: still a long way ahead of us
Galderisi, A. (2023) · Pediatric Endocrinology Diabetes and Metabolism · doi:10.5114/pedm.2023.126360 · Cited by 2
Zhao, Z., Gu, Y., Cheng, J., & Yu, L. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.75515 · Cited by 2
Self-citation
Metadata
- Authors
- Sosenko, J. M., Skyler, J. S., Palmer, J. P., Krischer, J. P., Yu, L., Mahon, J., Beam, C. A., Boulware, D. C., Rafkin, L., Schatz, D., Eisenbarth, G., & Groups, T. T. 1. D. T. A. T. D. P. T. 1. S.
- Affiliations
- University of Miami (US)
- University of Washington (US)
- University of South Florida (US)
- HLA/DNA Laboratory, Barbara Davis Center for Childhood Diabetes, Denver, Colorado
- Western University (CA)
- University of Florida Health (US)
- Corresponding author
- the Type 1 Diabetes TrialNet and the Diabetes Prevention Trial–Type 1 Study Groups
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-08-13
- Volume
- 36
- Issue
- 9
- Pages
- 2615-2620
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3747899
- OpenAlex
- W1992564715
- Cited by
- 123
- References
- 32
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 11 · 2023: 9 · 2022: 8 · 2021: 10 · 2020: 9 · 2019: 10 · 2018: 4 · 2017: 8 · 2016: 12 · 2015: 12 · 2014: 17 · 2013: 4
- FWCI
- 9.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Cambridge University Engineering Department Publications Database (submittedVersion)
- Funders
- American Diabetes Association
- National Institutes of Health (UL1TR000093, 5ul1rr031986-02, HHSN267200800019C, UL1TR001085, UL1TR000130, UL1TR000005, RR025780, DK017047)
- National Institute of Allergy and Infectious Diseases
- National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK-084565, DK017047, U01DK061040, U01DK085461, U01DK085505, 017047, U01DK085499, UL1-RR-024139, U01DK061055, U01DK061036, U01DK061010, U01DK061058, U01DK061034, U01DK061042, U01DK085463, U01DK085453, UC4DK117009, U01DK061041, U01DK085466, UC4DK097835, U01DK085509, U01 DK-061016, P30DK017047)
- National Institute of Child Health and Human Development
- U.S. National Library of Medicine (HHSN267200800019C)
- National Center for Research Resources (UL1RR029890, UL1RR024131, M01RR000400, UL1-RR031986, UL1RR025744, UL1RR024153, UL1RR024982, UL1RR025761, M01-RR00400, UL1RR024975, UL1RR024139, UL1RR025780)
- National Center for Advancing Translational Sciences
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN267200800019C)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- type 1 diabetes, islet autoantibodies, disease prediction, GADA, IA-2A, MiaA, Ica, ZnT8A, autoantibody levels
- MeSH terms
- Adolescent, Adult, Autoantibodies, Child, Child, Preschool, Diabetes Mellitus, Type 1, Female, Humans, Male, Risk Factors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.